SOPH · Insider Trading

SOPHiA GENETICS SA Ordinary Shares

Every open-market purchase and sale reported by SOPH officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.

Form 4 Filings
50
most recent
Open-Market Buys
0
code P
Sales
45
code S
Reporting Insiders
14
current holders
SOPH — Recent Form 4 Transactions (latest 2026-10-14)
FiledInsiderRole TypeSharesValue
2026-10-14 Philippe Menu Chief Medical Officer Sell −5,000 −$36.30K
2026-10-14 Jurgi Camblong Executive Chairman Sell −8,500 −$61.67K
2026-10-14 Zhenyu Xu Chief Scientific Officer Sell −4,000 −$28.73K
2026-10-07 George Cardoza Chief Financial Officer Sell −1,592 −$12.90K
2026-10-07 Zhenyu Xu Chief Scientific Officer Sell −7,394 −$60.07K
2026-10-07 Jurgi Camblong Executive Chairman Sell −40,172 −$326.53K
2026-10-07 Daan Van Well Chief Legal Officer Sell −6,168 −$50.10K
2026-10-07 Manuela Valente Chief People Officer Sell −4,240 −$34.49K
2026-10-07 Kevin Puylaert Chief Sales Officer Sell −216 −$1.74K
2026-10-07 Abhimanyu Verma Chief Technology Officer Sell −5,284 −$42.93K
2026-10-07 Philippe Menu Chief Medical Officer Sell −7,394 −$60.10K
2026-10-07 Ross Muken Chief Executive Officer Sell −9,838 −$79.97K
2026-09-22 Ross Muken Chief Executive Officer Sell −422 −$3.52K
2026-09-22 George Cardoza Chief Financial Officer Sell −774 −$6.45K
2026-09-16 Zhenyu Xu Chief Scientific Officer Sell −4,000 −$31.54K
2026-09-16 Philippe Menu Chief Medical Officer Sell −5,000 −$39.42K
2026-09-14 Jurgi Camblong Executive Chairman Sell −8,500 −$65.12K
2026-09-14 Daan Van Well Chief Legal Officer Sell −6,168 −$47.09K
2026-09-10 Kathy L Hibbs Director Sell −6,250 −$50.82K
2026-08-31 Zhenyu Xu Chief Scientific Officer Sell −10,000 −$89.10K
2026-08-26 Abhimanyu Verma Chief Technology Officer Sell −10,000 −$85.00K
2026-08-26 Philippe Menu Chief Medical Officer Sell −5,000 −$43.40K
2026-08-26 Kathy L Hibbs Director Sell −6,250 −$54.23K
2026-08-21 Manuela Valente Chief People Officer MIXED — −$47.44K
2026-08-21 Zhenyu Xu Chief Scientific Officer Sell −20,000 −$163.48K
2026-08-14 Philippe Menu Chief Medical Officer Sell −5,000 −$37.58K
2026-08-14 Zhenyu Xu Chief Scientific Officer Sell −4,000 −$30.08K
2026-08-10 Abhimanyu Verma Chief Technology Officer Sell −5,000 −$38.00K
2026-08-10 Jurgi Camblong Executive Chairman Sell −28,500 −$209.21K
2026-08-07 Zhenyu Xu Chief Scientific Officer MIXED −10,000 −$112.12K
2026-08-05 Jurgi Camblong Executive Chairman Sell −20,000 −$138.41K
2026-08-05 Abhimanyu Verma Chief Technology Officer Sell −5,000 −$34.77K
2026-08-05 Zhenyu Xu Chief Scientific Officer Sell −10,000 −$69.17K
2026-07-28 Philippe Menu Chief Medical Officer Sell −5,000 −$28.31K
2026-07-22 Jurgi Camblong Executive Chairman MIXED −39,800 −$271.62K
2026-07-14 Jurgi Camblong Executive Chairman Sell −8,500 −$47.79K
2026-07-14 Zhenyu Xu Chief Scientific Officer Sell −4,000 −$22.82K
2026-07-14 Philippe Menu Chief Medical Officer Sell −5,000 −$28.50K
2026-07-08 Jurgi Camblong Executive Chairman Sell −17,685 −$93.33K
2026-07-07 Manuela Valente Chief People Officer Sell −4,241 −$21.43K
2026-07-07 Jurgi Camblong Executive Chairman Sell −22,486 −$118.16K
2026-07-07 Ross Muken Chief Executive Officer Sell −9,838 −$51.35K
2026-07-07 Abhimanyu Verma Chief Technology Officer Sell −5,285 −$26.96K
2026-07-07 Zhenyu Xu Chief Scientific Officer Sell −7,393 −$38.24K
2026-07-07 Philippe Menu Chief Medical Officer Sell −7,393 −$38.16K
2026-07-07 Kevin Puylaert Chief Sales Officer Sell −216 −$1.09K
2026-07-07 George Cardoza Chief Financial Officer Sell −1,592 −$8.42K
2026-07-01 Jurgi Camblong Executive Chairman MIXED −20,200 −$306.10K
2026-06-29 Jurgi Camblong Chief Executive Officer MIXED −19,502 −$197.22K
2026-06-26 Abhimanyu Verma Chief Technology Officer Sell −6,944 −$38.23K
SOPH — Current Insider Holders
InsiderRole Shares HeldValue
Jurgi Camblong Executive Chairman 3,387,150 $25.47M
Ross Muken Chief Executive Officer 660,391 $4.97M
Zhenyu Xu Chief Scientific Officer 541,493 $4.07M
Vincent Ossipow Director 522,860 $3.93M
Daan Van Well Chief Legal Officer 332,716 $2.50M
Troy Cox Director 328,743 $2.47M
George Cardoza Chief Financial Officer 306,726 $2.31M
Didier Hirsch Director 240,220 $1.81M
Jean-Michel Cossery Director 206,212 $1.55M
Manuela Valente Chief People Officer 206,210 $1.55M
Philippe Menu Chief Medical Officer 195,993 $1.47M
Abhimanyu Verma Chief Technology Officer 166,887 $1.25M
Kevin Puylaert Chief Sales Officer 147,732 $1.11M
Kathy L Hibbs Director 96,992 $729.38K
SOPH Insider Trading FAQ
Who are the insiders at SOPH?
14 officers, directors and 10%+ beneficial owners currently report holdings in SOPH via SEC Form 4.
Are SOPH insiders buying or selling?
Across the 50 most recent Form 4 filings for SOPH, 0 were open-market purchases (code P) and 45 were sales (code S). Sales frequently reflect scheduled 10b5-1 plans or tax withholding rather than a view on the stock.
How current is SOPH insider data?
Form 4 must be filed within two business days of the transaction, so this is close to real time. The most recent SOPH filing is dated 2026-10-14.
How to read Form 4 activity

Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.

Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.

Full filing history and per-insider positions are on the SOPH quote page; the site-wide leaderboard is on the insider transactions hub.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.